

COVID-19 UPDATE

Keeping You Safe



Thunder Bay Regional
Health Sciences
Centre

To: Infectious Diseases, Critical Care Physicians, All Prescribers, Pharmacy

From: Carina Desramaux, Pharmacy Manager

Date: October 7, 2021

RE: **Casirivimab and Imdevimab for COVID-19**

The TBRHSC inpatient pharmacy has received a limited supply of casirivimab and imdevimab anti-SARS-CoV-2 spike protein monoclonal antibodies. These monoclonal antibodies have shown to improve patient outcomes when used in combination for the treatment of mildly, moderately, and critically ill, hospitalized patients with COVID-19 as per Ontario Science Advisory Table (SAT) guidelines¹.

The ON SAT recommends strict use criteria with a 1200 mg dose for mild COVID-19 and 8000 mg for moderate-critical COVID-19¹.

We currently have two 8000 mg doses for future use.

Due to complex usage criteria, casirivimab and imdevimab are **restricted to and may ONLY be ordered by Infectious Diseases and Critical Care physicians.**

- Infectious Diseases physician may order alone outside of ICU.
- Within ICU, two of these physicians are required to agree on casirivimab and imdevimab treatment for a patient prior to initiation of therapy (with documented agreement in chart). Infectious Diseases physician must be one of the approvers when available.

Casirivimab and imdevimab will be prepared in pharmacy sterile room during daytime pharmacy hours only at this time.

Please refer to the attached casirivimab and imdevimab parenteral manual for additional information.

Please contact Pharmacy if any questions.

Thank you,
Carina Desramaux, RPh
Pharmacy Manager
desramac@tbh.net 684-6327

References:

1. ON SAT Brief: Evidence-Based Recommendations on the Use of Casirivimab + Imdevimab, and Sotrovimab for Adults in Ontario (published September 30, 2021)
<https://covid19-sciencetable.ca/sciencebrief/evidence-based-recommendations-on-the-use-of-casirivimab-imdevimab-and-sotrovimab-for-adults-in-ontario/>